Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

PURPOSE: The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity th...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Oncol
Glavni autori: Frey, Noelle V., Shaw, Pamela A., Hexner, Elizabeth O., Pequignot, Edward, Gill, Saar, Luger, Selina M., Mangan, James K., Loren, Alison W., Perl, Alexander E., Maude, Shannon L., Grupp, Stephan A., Shah, Nirav N., Gilmore, Joan, Lacey, Simon F., Melenhorst, Jos J., Levine, Bruce L., June, Carl H., Porter, David L.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2020
Teme:
ORIGINAL REPORTS
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8312030/
https://ncbi.nlm.nih.gov/pubmed/31815579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01892
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items